Tolerability and Safety of the Intravenous Immunoglobulin Octagam® 10% in Patients With Immune Thrombocytopenia: A Post-Authorisation Safety Analysis of Two Non-Interventional Phase IV Trials
Hematology - United Kingdom
doi 10.1080/10245332.2017.1385892
Full Text
Open PDFAbstract
Available in full text
Categories
Date
October 11, 2017
Authors
Publisher
Informa UK Limited